1. Home
  2. ALX vs NTLA Comparison

ALX vs NTLA Comparison

Compare ALX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALX
  • NTLA
  • Stock Information
  • Founded
  • ALX 1928
  • NTLA 2014
  • Country
  • ALX United States
  • NTLA United States
  • Employees
  • ALX N/A
  • NTLA N/A
  • Industry
  • ALX Real Estate Investment Trusts
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • ALX Real Estate
  • NTLA Health Care
  • Exchange
  • ALX Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • ALX 1.2B
  • NTLA 1.2B
  • IPO Year
  • ALX N/A
  • NTLA 2016
  • Fundamental
  • Price
  • ALX $221.44
  • NTLA $10.86
  • Analyst Decision
  • ALX
  • NTLA Buy
  • Analyst Count
  • ALX 0
  • NTLA 20
  • Target Price
  • ALX N/A
  • NTLA $32.30
  • AVG Volume (30 Days)
  • ALX 50.6K
  • NTLA 4.6M
  • Earning Date
  • ALX 08-04-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • ALX 8.13%
  • NTLA N/A
  • EPS Growth
  • ALX N/A
  • NTLA N/A
  • EPS
  • ALX 7.28
  • NTLA N/A
  • Revenue
  • ALX $218,089,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • ALX N/A
  • NTLA N/A
  • Revenue Next Year
  • ALX N/A
  • NTLA N/A
  • P/E Ratio
  • ALX $29.65
  • NTLA N/A
  • Revenue Growth
  • ALX N/A
  • NTLA 14.99
  • 52 Week Low
  • ALX $184.76
  • NTLA $5.90
  • 52 Week High
  • ALX $260.84
  • NTLA $24.16
  • Technical
  • Relative Strength Index (RSI)
  • ALX 40.03
  • NTLA 44.54
  • Support Level
  • ALX $210.99
  • NTLA $10.57
  • Resistance Level
  • ALX $228.94
  • NTLA $11.54
  • Average True Range (ATR)
  • ALX 8.18
  • NTLA 0.79
  • MACD
  • ALX -4.01
  • NTLA -0.32
  • Stochastic Oscillator
  • ALX 20.96
  • NTLA 7.73

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: